Aclaris Therapeutics, Inc. ACRS 深 沪
等待开盘 03-26 09:30:00 美东时间
3.605
+0.305
+9.24%
华盛通- 最 高3.605
- 今 开3.32
- 成交量 101.11万股
- 最 低 3.32
- 昨 收 3.30
- 总市值 4.37亿
- 52周最高 4.89
- 市盈率 静 --
- 换手率 0.84%
- 52周最低 1.05
- 委 比 -18.47%
- 总股本 1.21亿
- 历史最高 33.88
- 量 比 0.83
- 振 幅 8.64%
- 历史最低 0.5902
- 每 手 1
- 风险率 0.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高700美元！大摩、瑞银等10家大行集体上调美光目标价；通用磨坊、梅西百货、SailPoint等遭多家大行下调目标价
今日重点评级关注：RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从32美元升至35美元；巴克莱：维持CytomX医疗"超配"评级，目标价从10美元升至16美元
03-20 15:53
HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and maintains $16 price target.
03-19 20:12
BRIEF-Aclaris Therapeutics Completes Enrollment In Phase 2 Trial Of Bosakitug (Ati-045) In Atopic Dermatitis
BRIEF-Aclaris Therapeutics Completes Enrollment In Phase 2 Trial Of Bosakitug (Ati-045) In Atopic Dermatitis March 18 (Reuters) - Aclaris Therapeutics Inc ACRS.O : ACLARIS THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2 TRIAL OF BOSAKITUG (ATI-045) IN ATOPIC DERMATITIS ACLARIS THERAPEUTICS INC - TOP LI
03-18 19:20
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer
Helus Pharma appoints Jill Conwell as Chief People Officer, leveraging her over 20 years of leadership experience in organizational strategy and talent development to support the company’s growth and clinical pipeline advancement. Conwell, who has held senior roles at prominent life sciences companies, will help attract top talent, enhance culture, and scale operations. Helus Pharma, which focuses on developing novel serotonergic agonists (NSAs) ...
03-12 11:30
Aclaris Therapeutics Raises Capital via Institutional Stock Sale
Aclaris Therapeutics ( ($ACRS) ) has provided an announcement. From March 2 to ...
03-10 20:40
Aclaris Therapeutics to Participate in Leerink Partners Global Healthcare Conference Fireside Chat
Aclaris Therapeutics to Participate in Leerink Partners Global Healthcare Conference Fireside Chat Aclaris Therapeutics Inc. said its CEO Dr. Neal Walker and other senior leaders will join a fireside chat at the Leerink Partners 2026 Global Healthcare Conference in Miami on March 10, 2026 at 1:40 PM
03-03 20:01
Aclaris Therapeutics Q4 EPS $(0.16) Misses $(0.14) Estimate, Sales $1.295M Miss $1.938M Estimate
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 11.11 percent. This is a 60 percent decrease over losses of $(0.10) per share
02-26 20:14
Aclaris Therapeutics Q4 Earnings Summary & Key Takeaways
Aclaris Therapeutics (NASDAQ:ACRS) reported its Q4 earnings results on Thursday...
02-26 20:14
Aclaris posts Q4 net loss of USD 19.8 million (-79.5%)
Aclaris posts Q4 net loss of USD 19.8 million (-79.5%) Aclaris reported a net loss of USD 19.8 million in Q4 2025 and USD 64.9 million for FY 2025. Total revenue was USD 1.3 million in Q4 2025 and USD 7.8 million in FY 2025. R&D expenses rose to USD 16.6 million in Q4 2025 and USD 52.6 million in FY
02-26 19:58
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052
Aclaris Therapeutics has initiated a Phase 1b, placebo-controlled trial for ATI-052, a bispecific anti-TSLP/IL-4Rα antibody, targeting asthma. Earlier, they began a similar trial in atopic dermatitis (AD). Both trials aim to assess safety, tolerability, and efficacy, with top-line results expected by mid-2026. A Phase 2b program for asthma and AD could follow. ATI-052 inhibits TSLP and IL-4Rα, addressing multiple inflammatory pathways linked to a...
02-24 12:00
